Výsledky vyhledávání - "JULIANA M. BUE-VALLESKEY"

Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial

Autor: Juliana M. Bue-Valleskey, Christof M. Kazda, Chenchen Ma, Jenny Chien, Qianyi Zhang, Emmanuel Chigutsa, William Landschulz, Axel Haupt, Juan P. Frias

Publikováno v: Diabetes Care. 46:1060-1067

OBJECTIVE Basal insulin Fc (BIF) (insulin efsitora alfa; LY3209590), a fusion protein combining a novel single-chain insulin variant with a human IgG Fc domain, is designed for once-weekly basal insulin administration. This phase 2 study assessed the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::554f271b1679eb8ceb0cb386d844a4f3
https://doi.org/10.2337/dc22-2396

Zobrazit plný text záznamu

Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes

Autor: Christof M. Kazda, Juliana M. Bue-Valleskey, Jenny Chien, Qianyi Zhang, Emmanuel Chigutsa, William Landschulz, Paula Wullenweber, Axel Haupt, Dominik Dahl

Publikováno v: Diabetes Care. 46:1052-1059

OBJECTIVE Basal Insulin Fc (BIF; insulin efsitora alfa; LY3209590), a fusion protein combining a novel single-chain insulin variant with a human IgG Fc domain, is designed for once-weekly basal insulin administration. This phase 2 study assessed safe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b09912fe9e31ff8d441e60a36156d404
https://doi.org/10.2337/dc22-2395

Zobrazit plný text záznamu

Once Weekly Basal Insulin Fc (BIF) Demonstrated Similar Glycemic Control to Once Daily Insulin Degludec in Insulin-naïve Patients with Type 2 Diabetes, A Phase 2 Randomized Control Trial

Autor: Juan P Frias, Axel Haupt, William Landschulz, Emmanuel Chigutsa, Qianyi Zhang, Jenny Chien, Chenchen Ma, Christof M. Kazda, Juliana M. Bue-Valleskey

Objective Basal Insulin Fc (BIF; insulin efsitora alfa; LY3209590), a fusion protein combining a novel single-chain insulin variant with a human IgG Fc domain, is designed for once weekly basal insulin administration. This Phase 2 study assessed safe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba55ec3ef95c4b06033de195efe843fe
https://doi.org/10.2337/figshare.22144145

Zobrazit plný text záznamu

Novel Once Weekly Basal Insulin Fc (BIF) Achieved Similar Glycemic Control with A Comparable Safety Profile Versus Insulin Degludec in Patients with Type 1 Diabetes (T1D)

Autor: Dominik Dahl, Axel Haupt, Paula Wullenweber, William Landschulz, Emmanuel Chigutsa, Qianyi Zhang, Jenny Chien, Juliana M. Bue-Valleskey, Christof M. Kazda

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59277701874b73067fb13cca6fe732d1
https://doi.org/10.2337/figshare.22141748

Zobrazit plný text záznamu

Long-Term Efficacy and Safety of Ultra Rapid Lispro (URLi) in Adults with Type 1 Diabetes: The PRONTO-T1D Extension

Autor: Juliana M. Bue-Valleskey, Leslie J. Klaff, Nanette C. Schloot, Janet Tobian, Mary Anne Dellva, Jang Ik Cho, Dominik Dahl, Junnosuke Miura

Publikováno v: Diabetes Therapy

Introduction The PRONTO-T1D study, which evaluated the efficacy and safety of ultra rapid lispro (URLi) versus lispro in adults with type 1 diabetes (T1D), met the primary endpoint of noninferiority of HbA1c change from baseline compared to lispro at

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e70ae4e55195439b972f4884129c42f8
https://doi.org/10.1007/s13300-020-00987-8

Zobrazit plný text záznamu

Plný text ve formátu HTML

215-OR: Once Weekly (QW) Basal Insulin Fc (BIF) Demonstrated Similar Glycemic Control to Once Daily (QD) Insulin Degludec (DEG) in Insulin-Naïve Patients with Type 2 Diabetes (T2D)

Autor: JULIANA M. BUE-VALLESKEY, CHRISTOF M. KAZDA, CHENCHEN MA, JENNY CHIEN, QIANYI ZHANG, EMMANUEL CHIGUTSA, WILLIAM LANDSCHULZ, JENNIFER SWAN, AXEL HAUPT, JUAN PABLO FRIAS

Publikováno v: Diabetes. 71

Basal Insulin Fc (BIF; LY3209590) , a fusion protein combining a novel single-chain insulin variant with a human IgG Fc domain, is designed for QW administration. This randomized, parallel, open-label Ph2 study assessed safety and efficacy of BIF vs.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dd81c598289c43c859631cd2b112b458
https://doi.org/10.2337/db22-215-or

Zobrazit plný text záznamu

Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26‐week PRONTO‐T1D study

Autor: Juliana M. Bue-Valleskey, Dachuang Cao, Dominik Dahl, Junnosuke Miura, Janet Tobian, Jean Lucas, Mary Anne Dellva, Leslie J. Klaff

Publikováno v: Diabetes, Obesity & Metabolism

Aims To evaluate the efficacy and safety of ultra rapid lispro (URLi) versus lispro in adults with type 1 diabetes in a 26‐week, treat‐to‐target, phase 3 trial. Materials and methods After an 8‐week lead‐in to optimize basal insulin glargin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6919b0f1fc37568dad2ba3fbd7e81aac
https://doi.org/10.1111/dom.14100

Zobrazit plný text záznamu

Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study

Autor: Eric Zijlstra, Christoph Kapitza, Qianyi Zhang, Helle Linnebjerg, Juliana M. Bue-Valleskey, David E. Coutant, Jennifer Leohr, Tim Heise, Elizabeth Smith Labell, Mary Anne Dellva

Publikováno v: Diabetes, Obesity & Metabolism

Aims To compare the pharmacokinetic (PK) and glucodynamic (GD) characteristics of ultra rapid lispro (URLi; Eli Lilly and Company, Indianapolis, Indiana), Fiasp® (Novo Nordisk, Bagsvaerd, Denmark), Humalog® (Eli Lilly and Company) and NovoRapid® (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5389cfce7345fb4921d7a00fbf48d12c
http://europepmc.org/articles/PMC7540588

Zobrazit plný text záznamu

232-OR: Long-Term Safety and Efficacy of Ultra-Rapid Lispro (URLi) in PRONTO-T1D

Autor: Junnosuke Miura, Juliana M. Bue-Valleskey, Leslie J. Klaff, Janet Tobian, Nanette C. Schloot, Dominik Dahl, Jang Ik Cho, Mary Anne Dellva

Publikováno v: Diabetes. 69

PRONTO T1D was a phase 3 study evaluating ultra rapid lispro (URLi) in adults with type 1 diabetes (T1D) for 52 weeks. Subjects were randomized to double-blind mealtime URLi, Humalog, or open-label postmeal URLi with insulin degludec or glargine for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bddb2a91ee46525a2f0ba7f6755df8ed
https://doi.org/10.2337/db20-232-or

Zobrazit plný text záznamu

1044-P: The Impact of Basal Insulin Type, Prandial Dosing Plan, and Baseline Postprandial Glucose (PPG) on Glycemic Control after Treatment with Ultra-Rapid Lispro (URLi) or Humalog in Type 1 Diabetes: Planned Subgroup Analyses from PRONTO-T1D

Autor: Juliana M. Bue-Valleskey, Thomas Hardy, Jang Ik Cho

Publikováno v: Diabetes. 69

URLi is a novel prandial insulin lispro formulation developed to more closely match physiological insulin secretion and improve PPG control. In PRONTO-T1D, a phase 3, 26-week, treat-to-target study comparing URLi to Humalog in patients with T1D on a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::03c47a96c10bac3d3a09057d8fbd2cea
https://doi.org/10.2337/db20-1044-p

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání